Houston、TXにおける食道癌の臨床試験
Houstonとその周辺地域（約30マイル以内）の拠点で、食道癌に関する36件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
被験者募集中第1相
- University of Texas MD Anderson Cancer Center, Houston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
被験者募集中第2相
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- UT MD Anderson Cancer Center, Houston
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
被験者募集中第2相
- The University of Texas MD Anderson Cancer Center, Houston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
被験者募集中第1相
- University of Texas MD Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
被験者募集中第2相
- MD Anderson Cancer Center (Data Collection Only), Houston
Pan-tumor MRD Study
被験者募集中観察研究
- Onocology Consultants P.A. (Oncology Consultants [OC Houston]), Houston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
被験者募集中第1相
- MD Anderson Cancer Center, Houston
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
被験者募集中第1相
- Baylor College of Medicine, Houston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
被験者募集中第1/2相
- MD Anderson, Houston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
被験者募集中第1相
- Oncology Consultants, P.A., Houston
- University of Texas M.D. Anderson Cancer Center, Houston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
被験者募集中第1相
- Oncology Consultants, Houston
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
被験者募集中第3相
- Research Site, Houston
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
被験者募集中第1/2相
- University of Texas MD Anderson Cancer Center ( Site 8920), Houston
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
被験者募集中第1/2相
- University of Texas MD Anderson Cancer Center ( Site 6920), Houston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- The University of Texas, MD Anderson Cancer Center, Houston
IDOV-Immune for Advanced Solid Tumors
被験者募集中第1相
- MD Anderson Cancer Center, Houston
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- Oncology Consultants, Houston
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
被験者募集中第2相
- MD Anderson Cancer Center, Houston
Lead-212 PSV359 Therapy for Patients With Solid Tumors
被験者募集中第1/2相
- MD Anderson Cancer Center, Houston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
被験者募集中第1相
- Oncology Consultants, PA, Houston
- Oncology Consultants, PA., Houston
- The University of Texas M.D. Anderson Cancer Center, Houston
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
被験者募集中第1相
- The University of Texas MD Anderson Cancer Center /ID# 270059, Houston
Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
被験者募集中観察研究
- M D Anderson Cancer Center, Houston
Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation
被験者募集中観察研究健康なボランティア歓迎
- MD Anderson Cancer Center, Houston
18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer
被験者募集中第1相
- MD Anderson Cancer Center, Houston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- MD Anderson Cancer Center, Houston
Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers
被験者募集中健康なボランティア歓迎
- M D Anderson Cancer Center, Houston
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
被験者募集中第2相
- M D Anderson Cancer Center, Houston
Novel Bipolar Radiofrequency Ablation Knife in Esophageal Lesions
被験者募集中観察研究
- Baylor College of Medicine, Houston
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
被験者募集中観察研究
- Md Anderson Cancer Center, Houston
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
被験者募集中第1相
- Baylor St. Luke's Medical Center, Houston
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
被験者募集中第1相
- Oncology Consultants, Houston
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
被験者募集中第1/2相
- The University of Texas MD Anderson Cancer Center, Houston
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
被験者募集中第1/2相
- The University of Texas MD Anderson Cancer Center (site 127), Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Houston
Distribution of Lymph Node Metastases in Esophageal Carcinoma
被験者募集中観察研究
- MD Anderson Cancer Center, Houston
他の都市における食道癌の試験
- Boston, MA23件の研究
- New York City, NY22件の研究
- Nashville, TN19件の研究
- St. Louis, MO17件の研究
- Pittsburgh, PA15件の研究
- Los Angeles, CA15件の研究
- Baldwin Park, CA14件の研究
- Grand Rapids, MI14件の研究
- Philadelphia, PA13件の研究
- San Antonio, TX12件の研究
- Rochester, MN11件の研究
- Arlington, VA11件の研究
Houstonにおける他の研究
- 非小細胞肺癌145件の研究
- 乳がん126件の研究
- がん（全種類）121件の研究
- 転移性癌104件の研究
- 大腸癌102件の研究
- 卵巣がん89件の研究
- 急性骨髄性白血病85件の研究
- 肺がん78件の研究
- 前立腺がん76件の研究
- 子宮内膜がん68件の研究
- 膵臓がん61件の研究
- 悪性黒色腫59件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。